title: Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease.
abstract: BACKGROUND
  Serum copper not bound to ceruloplasmin ("free") appears slightly elevated in patients with Alzheimer disease (AD). We explored whether a deregulation of the free copper pool can predict AD clinical worsening.
  
  
  METHODS
  We assessed levels of copper, iron, zinc, transferrin, ceruloplasmin, peroxides, total antioxidant capacity, free copper, and apolipoprotein E genotype in 81 patients with mild or moderate AD, mean age 74.4, SD = 7.4 years, clinically followed up after 1 year. The association among biologic variables under study and Mini-Mental State Examination (MMSE) (primary outcome), activities of daily living (ADL), and instrumental activities of daily living (IADL) (secondary outcomes) performed at study entry and after 1 year were analyzed by multiple regression.
  
  
  RESULTS
  Free copper predicted the annual change in MMSE, adjusted for the baseline MMSE by means of a linear regression model: it raised the explained variance from 2.4% (with only sex, age, and education) to 8.5% (p = 0.026). When the annual change in MMSE was divided into < 3 or > or = 3 points, free copper was the only predictor of a more severe decline (predicted probability of MMSE worsening 23%: odds ratio = 1.23; 95% confidence interval = 1.03-1.47; p = 0.022). Hyperlipidemic patients with higher levels of free copper seemed more prone to worse cognitive impairment. Free copper at baseline correlated with the ADL and IADL clinical scales scores at 1 year.
  
  
  CONCLUSIONS
  These results show an association between copper deregulation and unfavorable evolution of cognitive function in Alzheimer disease. Further research is needed to establish whether copper is an independent risk factor for cognitive decline.
authors.affiliation: Department of Neuroscience, AFaR-Osp. Fatebenefratelli, 00186, Rome, Italy. rosanna.squitti@afar.it
authors.forename: R
authors.initials: R
authors.lastname: Squitti
authors.forename: F
authors.initials: F
authors.lastname: Bressi
authors.forename: P
authors.initials: P
authors.lastname: Pasqualetti
authors.forename: C
authors.initials: C
authors.lastname: Bonomini
authors.forename: R
authors.initials: R
authors.lastname: Ghidoni
authors.forename: G
authors.initials: G
authors.lastname: Binetti
authors.forename: E
authors.initials: E
authors.lastname: Cassetta
authors.forename: F
authors.initials: F
authors.lastname: Moffa
authors.forename: M
authors.initials: M
authors.lastname: Ventriglia
authors.forename: F
authors.initials: F
authors.lastname: Vernieri
authors.forename: P M
authors.initials: PM
authors.lastname: Rossini
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood* / Q000150:complications*; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology*; D003300:Copper / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D011237:Predictive Value of Tests; D011336:Probability; D011379:Prognosis; D012307:Risk Factors; D013223:Statistics as Topic
chemical_list: D003300:Copper